zacks.com · 3 jul

Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?

NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.

gurufocus.com · 2 jul

Novo Nordisk AS (NVO) Stock Up 3.4% and Still Undervalued -- GF Score: 76/100

On July 02, 2026, Novo Nordisk AS (NVO) shares rose 3.4% today, bringing the current price to $50.43. The stock has experienced a wide 52-week range, with a hig

proactiveinvestors.com · 2 jul

Microsoft to invest $2.5B in new AI implementation business

Microsoft Corp (NASDAQ:MSFT) announced a $2.5 billion investment to launch Microsoft Frontier Company, a new operating business focused on helping...

zacks.com · 1 jul

Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note

In the latest trading session, Novo Nordisk (NVO) closed at $48.77, marking a +1.73% move from the previous day.

zacks.com · 1 jul

Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

247wallst.com · 30 jun

AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

cnbc.com · 30 jun

Medicare will start covering obesity drugs for the first time. Here's what patients should know

Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge. The move could unlock a vast new patient population for Novo Nordisk and Eli Lilly and dramatically expand access to medications that were previously out of reach for many older Americans.

zacks.com · 29 jun

Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?

NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.